Biostar Pharmaceuticals, Inc. Gross Margin
- Gross margin · 12 months: Value -11.56%; Formula and calculation Gross profit / revenue. Period ending 2017-09-30..
Gross margin
Overview →Financial period ending 2017-09-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | -11.56% | Gross profit / revenue. Period ending 2017-09-30. $-36.75K ÷ $317.79K × 100 ≈ -11.56% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | -36.75K USD | Gross Profit |
| Revenue | 317.79K USD | |
| Cost of products and services | 354.54K USD | Cost of Goods and Services Sold |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2017-09-30 | $-36.75K | $317.79K | $354.54K | -11.56% |
| 2017-06-30 | $271.32K | $962.73K | $691.41K | 28.18% |
| 2017-03-31 | $570.20K | $1.58M | $1.01M | 36.02% |
| 2016-12-31 | $915.17K | $2.38M | $1.47M | 38.38% |
| 2016-09-30 | $1.72M | $3.90M | $2.18M | 44.05% |
| 2016-06-30 | $2.23M | $7.47M | $5.24M | 29.84% |
| 2016-03-31 | $7.87M | $21.02M | $13.15M | 37.43% |
| 2015-12-31 | $11.10M | $27.13M | $16.03M | 40.93% |
| 2015-09-30 | $17.11M | $39.68M | $22.56M | 43.14% |
| 2015-06-30 | $23.28M | $50.12M | $26.85M | 46.44% |
| 2015-03-31 | $26.60M | $55.14M | $28.54M | 48.25% |
| 2014-12-31 | $30.28M | $61.42M | $31.14M | 49.30% |
| 2014-09-30 | $28.67M | $58.01M | $29.34M | 49.43% |
| 2014-06-30 | $28.64M | $58.37M | $29.73M | 49.06% |
| 2014-03-31 | $26.25M | $53.82M | $27.57M | 48.77% |
| 2013-12-31 | $25.68M | $52.73M | $27.05M | 48.71% |
| 2013-09-30 | $29.71M | $57.04M | $27.33M | 52.09% |
| 2013-06-30 | $28.01M | $52.00M | $23.99M | 53.86% |
| 2013-03-31 | $25.70M | $45.51M | $19.81M | 56.48% |
| 2012-12-31 | $29.85M | $49.32M | $19.47M | 60.53% |
| 2012-09-30 | $38.41M | $60.01M | $21.61M | 64.00% |
| 2012-06-30 | $50.48M | $74.82M | $24.34M | 67.47% |
| 2012-03-31 | $64.54M | $92.58M | $28.04M | 69.71% |
| 2011-12-31 | $64.39M | $91.97M | $27.58M | 70.01% |
| 2011-09-30 | $68.14M | $94.26M | $26.12M | 72.29% |
| 2011-06-30 | $65.54M | $89.66M | $24.12M | 73.10% |
| 2011-03-31 | (m) | (m) | (m) | (m) |
| 2010-12-31 | $60.14M | $80.21M | $20.08M | 74.97% |
| 2010-09-30 | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.